News
AstraZeneca (LSE:AZN) recently announced that its AIRSUPRA therapy significantly reduced severe asthma exacerbations, ...
AstraZeneca (AZN) says “positive” full results from the BATURA Phase IIIb trial showed the company’s anti-inflammatory reliever rescue therapy, Airsupra, demonstrated statistically significant and ...
Results from the pivotal BATURA trial show that Airsupra (albuterol/budesonide) significantly outperformed albuterol ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback